Mannkind (MNKD) Cash from Investing Activities (2010 - 2026)
Mannkind's (MNKD) quarterly Cash from Investing Activities came in at $18.7 million in Q1 2026, up 214.07% year-on-year from $6.0 million in Q1 2025, and up 106.41% on a QoQ basis from -$292.0 million in Q4 2025.
Mannkind (MNKD) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has 17 years of Cash from Investing Activities data on file, last reported at $18.7 million in Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 214.07% year-over-year to $18.7 million in Q1 2026; TTM through Mar 2026 was -$292.0 million, a 591.22% decrease from a year earlier, with the FY2025 full-year figure at -$304.8 million, down 215.37% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $18.7 million, up from -$292.0 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for MNKD reached as high as $48.2 million in Q4 2024 and fell as low as -$292.0 million in Q4 2025.
- Historically, Cash from Investing Activities has averaged -$22.3 million across 5 years, with a median of $2.0 million in 2022.
- On a YoY basis, Cash from Investing Activities climbed as much as 710.82% in 2024 and fell as far as 1606.0% in 2024.
- Year by year, Cash from Investing Activities stood at $15.0 million in 2022, then tumbled by 152.6% to -$7.9 million in 2023, then jumped by 710.82% to $48.2 million in 2024, then slumped by 705.43% to -$292.0 million in 2025, then surged by 106.41% to $18.7 million in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were $18.7 million in Q1 2026, -$292.0 million in Q4 2025, and -$25.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - | - |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Mannkind | 1.24 Bn | 1.11 Bn | 82.66 Mn | 18.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.73 Mn |
| Mar 31, 2026 | 18.73 Mn |
| Dec 31, 2025 | -291.96 Mn |
| Dec 31, 2025 | -291.96 Mn |
| Sep 30, 2025 | -25.06 Mn |
| Sep 30, 2025 | -25.06 Mn |
| Jun 30, 2025 | 6.26 Mn |
| Jun 30, 2025 | 6.26 Mn |
| Mar 31, 2025 | 5.96 Mn |
| Mar 31, 2025 | 5.96 Mn |
| Dec 31, 2024 | 48.22 Mn |
| Dec 31, 2024 | 48.22 Mn |
| Sep 30, 2024 | -41.26 Mn |
| Sep 30, 2024 | -41.26 Mn |
| Jun 30, 2024 | -55.18 Mn |
| Jun 30, 2024 | -55.18 Mn |
| Mar 31, 2024 | -48.44 Mn |
| Mar 31, 2024 | -48.44 Mn |
| Dec 31, 2023 | -7.90 Mn |
| Dec 31, 2023 | -7.90 Mn |